- Home
- PODC vs TELO Comparison
PODC vs TELO Comparison
Compare PODC & TELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- TELO
- Stock Information
- Founded
- PODC 2013
- TELO 2021
- Country
- PODC United States
- TELO United States
- Employees
- PODC N/A
- TELO N/A
- Industry
- PODC
- TELO
- Sector
- PODC
- TELO
- Exchange
- PODC Nasdaq
- TELO NYSE
- Market Cap
- PODC 44.1M
- TELO 52.4M
- IPO Year
- PODC N/A
- TELO 2024
- Fundamental
- Price
- PODC $1.90
- TELO $2.19
- Analyst Decision
- PODC
- TELO
- Analyst Count
- PODC 0
- TELO 0
- Target Price
- PODC N/A
- TELO N/A
- AVG Volume (30 Days)
- PODC 105.3K
- TELO 9.2M
- Earning Date
- PODC 08-12-2025
- TELO 08-12-2025
- Dividend Yield
- PODC N/A
- TELO N/A
- EPS Growth
- PODC N/A
- TELO N/A
- EPS
- PODC N/A
- TELO N/A
- Revenue
- PODC $52,119,000.00
- TELO N/A
- Revenue This Year
- PODC $19.39
- TELO N/A
- Revenue Next Year
- PODC $23.41
- TELO N/A
- P/E Ratio
- PODC N/A
- TELO N/A
- Revenue Growth
- PODC 20.36
- TELO N/A
- 52 Week Low
- PODC $1.10
- TELO $1.12
- 52 Week High
- PODC $2.94
- TELO $8.40
- Technical
- Relative Strength Index (RSI)
- PODC 42.50
- TELO 64.07
- Support Level
- PODC $1.92
- TELO $2.00
- Resistance Level
- PODC $2.06
- TELO $2.44
- Average True Range (ATR)
- PODC 0.21
- TELO 0.19
- MACD
- PODC -0.04
- TELO 0.15
- Stochastic Oscillator
- PODC 12.93
- TELO 54.04
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About TELO TELOMIR PHARMACEUTICALS INC
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.